ContraFect Corporation (CFRX) financial statements (2021 and earlier)

Company profile

Business Address 28 WELLS AVENUE
YONKERS, NY 10701
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments24111423303833
Cash and cash equivalents2411778115
Short-term investments  716222729
Other undisclosed current assets7222122
Total current assets:31131625313935
Noncurrent Assets
Operating lease, right-of-use asset333 
Property, plant and equipment1111111
Other noncurrent assets0000000
Other undisclosed noncurrent assets   3   
Total noncurrent assets:4555111
TOTAL ASSETS:35172130334137
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9735655
Accounts payable3413131
Accrued liabilities7322434
Debt111    
Other undisclosed current liabilities   1   
Total current liabilities:10846655
Noncurrent Liabilities
Long-term debt and lease obligation333    
Operating lease, liability333 
Liabilities, other than long-term debt6243223639
Deferred rent credit    111
Other liabilities0000000
Derivative instruments and hedges, liabilities6243213539
Other undisclosed noncurrent liabilities   3   
Total noncurrent liabilities:9687223639
Total liabilities:19131212274244
Stockholders' equity
Stockholders' equity attributable to parent1649176(1)(7)
Common stock0000000
Additional paid in capital228206206205205205194
Accumulated other comprehensive income (loss)  00(0)(0)(0)
Accumulated deficit(212)(202)(196)(188)(199)(205)(201)
Total stockholders' equity:1649176(1)(7)
TOTAL LIABILITIES AND EQUITY:35172130334137

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(6)(8)(7)(6)(9)(8)(7)
Operating loss:(6)(8)(7)(6)(9)(8)(7)
Nonoperating income (expense)(4)2(1)18153(13)
Net income (loss) available to common stockholders, diluted:(10)(5)(9)126(4)(20)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(10)(5)(9)126(4)(20)
Comprehensive income (loss):(10)(5)(9)126(4)(20)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  00(0)00
Comprehensive income (loss), net of tax, attributable to parent:(10)(5)(9)126(4)(20)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: